Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hydrophobic Imbalance in the Cytoplasmic Domain of Phospholamban Is a Determinant for Lethal Dilated Cardiomyopathy

Ceholski, Delaine K., Trieber, Catharine A., Young, Howard S. · 2012 · Journal of Biological Chemistry

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m112.360859

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 54

  1. Dellefave, 2010, The genetics of dilated cardiomyopathy, Curr. Opin. Cardiol., 25, 198, 10.1097/HCO.0b013e328337ba52 · DOI · Paper page
  2. Kirchberber, 1975, Phospholamban. A regulatory protein of the cardiac sarcoplasmic reticulum, Recent Adv. Stud. Cardiac Struct. Metab., 5, 103
  3. Simmerman, 1986, Sequence Analysis of Phospholamban. Identification of Phosphorylation Sites and Two Major Structural Domains, J. Biol. Chem., 261, 13333, 10.1016/S0021-9258(18)69309-3 · doi:10.1016/s0021-9258(18)69309-3
  4. MacLennan, 2003, Phospholamban. A crucial regulator of cardiac contractility, Nat. Rev. Mol. Cell Biol., 4, 566, 10.1038/nrm1151 · DOI · Paper page
  5. Hasenfuss, 1994, Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium, Circ. Res., 75, 434, 10.1161/01.RES.75.3.434 · DOI · Paper page
  6. Minamisawa, 2003, Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy, Biochem. Biophys. Res. Commun., 304, 1, 10.1016/S0006-291X(03)00526-6 · DOI
  7. Haghighi, 2008, A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids, Hum. Mutat., 29, 640, 10.1002/humu.20692 · DOI
  8. Haghighi, 2003, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, J. Clin. Invest., 111, 869, 10.1172/JCI17892 · DOI · Paper page
  9. Landstrom, 2011, PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases. Summary of the literature and implications for genetic testing, Am. Heart J., 161, 165, 10.1016/j.ahj.2010.08.001 · DOI
  10. Schmitt, 2003, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science, 299, 1410, 10.1126/science.1081578 · DOI · Paper page
  11. DeWitt, 2006, Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy, J. Am. Coll. Cardiol., 48, 1396, 10.1016/j.jacc.2006.07.016 · DOI
  12. Haghighi, 2006, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, Proc. Natl. Acad. Sci. U.S.A., 103, 1388, 10.1073/pnas.0510519103 · DOI · Paper page
  13. Posch, 2009, Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes, Heart Rhythm, 6, 480, 10.1016/j.hrthm.2009.01.016 · doi:10.1016/j.hrthm.2009.01.016
  14. Medeiros, 2011, Mutations in the human phospholamban gene in patients with heart failure, Am. Heart J., 162, 1088, 10.1016/j.ahj.2011.07.028 · DOI
  15. Rapti, 2011, Targeted gene therapy for the treatment of heart failure, Can. J. Cardiol., 27, 265, 10.1016/j.cjca.2011.02.005 · DOI
  16. Ha, 2011, Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A, Proc. Natl. Acad. Sci. U.S.A., 108, 2735, 10.1073/pnas.1013987108 · DOI
  17. Douglas, 2005, Rapid, high-yield expression and purification of Ca2+-ATPase regulatory proteins for high-resolution structural studies, Protein Expr. Purif., 40, 118, 10.1016/j.pep.2004.11.015 · doi:10.1016/j.pep.2004.11.015
  18. Trieber, 2005, The effects of mutation on the regulatory properties of phospholamban in co-reconstituted membranes, Biochemistry, 44, 3289, 10.1021/bi047878d · doi:10.1021/bi047878d
  19. Eletr, 1972, Phospholipid orientation in sarcoplasmic reticulum membranes. Spin-label ESR and proton NMR studies, Biochim. Biophys. Acta, 282, 174, 10.1016/0005-2736(72)90321-5 · DOI · Paper page
  20. Stokes, 1990, Three-dimensional crystals of Ca-ATPase from sarcoplasmic reticulum. Symmetry and molecular packing, Biophys. J., 57, 1, 10.1016/S0006-3495(90)82501-7 · DOI
  21. Young, 2001, Locating phospholamban in co-crystals with Ca2+-ATPase by cryoelectron microscopy, Biophys. J., 81, 884, 10.1016/S0006-3495(01)75748-7 · DOI
  22. Reddy, 1996, Purified, reconstituted cardiac Ca2+-ATPase is regulated by phospholamban but not by direct phosphorylation with Ca2+/calmodulin-dependent protein kinase, J. Biol. Chem., 271, 14964, 10.1074/jbc.271.25.14964 · DOI
  23. Ferrington, 2002, Comparable levels of Ca-ATPase inhibition by phospholamban in slow-twitch skeletal and cardiac sarcoplasmic reticulum, Biochemistry, 41, 13289, 10.1021/bi026407t · DOI · Paper page
  24. Negash, 1996, Phosphorylation of phospholamban by cAMP-dependent protein Kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes, Biochemistry, 35, 11247, 10.1021/bi960864q · DOI
  25. Warren, 1974, Reconstitution of a calcium pump using defined membrane components, Proc. Natl. Acad. Sci. U.S.A., 71, 622, 10.1073/pnas.71.3.622 · DOI · Paper page
  26. Inesi, 1988, Kinetic and equilibrium characterization of an energy-transducing enzyme and its partial reactions, Methods Enzymol., 157, 154, 10.1016/0076-6879(88)57074-X · doi:10.1016/0076-6879(88)57074-x
  27. Cantilina, 1993, Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases. Effect of phospholamban antibody on enzyme activation, J. Biol. Chem., 268, 17018, 10.1016/S0021-9258(19)85295-X · DOI · Paper page
  28. Trieber, 2009, Effects of phospholamban transmembrane mutants on the calcium affinity, maximal activity, and cooperativity of the sarcoplasmic reticulum calcium pump, Biochemistry, 48, 9287, 10.1021/bi900852m · DOI
  29. Toyofuku, 1994, Amino acids Glu-2 to Ile-18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca-ATPase of sarcoplasmic reticulum, J. Biol. Chem., 269, 3088, 10.1016/S0021-9258(17)42051-5 · DOI · Paper page
  30. Hou, 2010, Relative affinity of calcium pump isoforms for phospholamban quantified by fluorescence resonance energy transfer, J. Mol. Biol., 402, 210, 10.1016/j.jmb.2010.07.023 · doi:10.1016/j.jmb.2010.07.023
  31. Reddy, 1999, Co-reconstitution of phospholamban mutants with the Ca-ATPase reveals dependence of inhibitory function on phospholamban structure, J. Biol. Chem., 274, 7649, 10.1074/jbc.274.12.7649 · doi:10.1074/jbc.274.12.7649
  32. Toyoshima, 2003, Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase, Proc. Natl. Acad. Sci. U.S.A., 100, 467, 10.1073/pnas.0237326100 · DOI · Paper page
  33. Stokes, 2006, Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals, Biophys. J., 90, 4213, 10.1529/biophysj.105.079640 · doi:10.1529/biophysj.105.079640
  34. Gustavsson, 2011, Activating and deactivating roles of lipid bilayers on the Ca2+-ATPase/phospholamban complex, Biochemistry, 50, 10367, 10.1021/bi200759y · DOI · Paper page
  35. Glaves, 2011, Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump, J. Mol. Biol., 405, 707, 10.1016/j.jmb.2010.11.014 · DOI
  36. Reddy, 1995, Functional reconstitution of recombinant phospholamban with rabbit skeletal Ca-ATPase, J. Biol. Chem., 270, 9390, 10.1074/jbc.270.16.9390 · doi:10.1074/jbc.270.16.9390
  37. Louis, 1987, Phospholamban stoichiometry in canine cardiac muscle sarcoplasmic reticulum, Neurochem. Res., 12, 937, 10.1007/BF00966316 · doi:10.1007/bf00966316
  38. Colyer, 1991, Dependence of cardiac sarcoplasmic reticulum calcium pump activity on the phosphorylation status of phospholamban, J. Biol. Chem., 266, 17486, 10.1016/S0021-9258(19)47398-5 · DOI
  39. Brittsan, 2000, Maximal inhibition of SERCA2 Ca2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban, J. Biol. Chem., 275, 12129, 10.1074/jbc.275.16.12129 · DOI
  40. Mishra, 2002, Molecular mechanisms of reduced sarcoplasmic reticulum Ca2+ uptake in human failing left ventricular myocardium, J. Heart Lung Transplant., 21, 366, 10.1016/S1053-2498(01)00390-4 · DOI
  41. Negash, 2000, Phospholamban remains associated with the Ca2+- and Mg2+-dependent ATPase following phosphorylation by cAMP-dependent protein kinase, Biochem. J., 351, 195, 10.1042/bj3510195 · doi:10.1042/bj3510195
  42. Karim, 2006, Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA, J. Mol. Biol., 358, 1032, 10.1016/j.jmb.2006.02.051 · DOI · Paper page
  43. Traaseth, 2006, Effects of Ser-16 phosphorylation on the allosteric transitions of phospholamban/Ca2+-ATPase complex, J. Mol. Biol., 358, 1041, 10.1016/j.jmb.2006.02.047 · DOI
  44. Kimura, 1997, Phospholamban inhibitory function is enhanced by depolymerization, J. Biol. Chem., 272, 15061, 10.1074/jbc.272.24.15061 · DOI · Paper page
  45. Grünig, 1998, Frequency and phenotypes of familial dilated cardiomyopathy, J. Am. Coll. Cardiol., 31, 186, 10.1016/S0735-1097(97)00434-8 · DOI · Paper page
  46. Chen, 2010, Ca2+ binding to site I of the cardiac Ca2+ pump is sufficient to dissociate phospholamban, J. Biol. Chem., 285, 3253, 10.1074/jbc.M109.080820 · doi:10.1074/jbc.m109.080820
  47. Akin, 2012, Characterizing phospholamban to SERCA2a binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking, J. Biol. Chem., 287, 7582, 10.1074/jbc.M111.334987 · doi:10.1074/jbc.m111.334987
  48. James, 1989, Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum, Nature, 342, 90, 10.1038/342090a0 · DOI · Paper page
  49. Chen, 2007, Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12, J. Biol. Chem., 282, 20968, 10.1074/jbc.M703516200 · doi:10.1074/jbc.m703516200
  50. Fowler, 1989, The effects of calcium, temperature, and phospholamban phosphorylation on the dynamics of the calcium-stimulated ATPase of canine cardiac sarcoplasmic reticulum, Biochim. Biophys. Acta, 980, 348, 10.1016/0005-2736(89)90323-4 · doi:10.1016/0005-2736(89)90323-4
  51. Bidwell, 2011, Phospholamban binds with differential affinity to calcium pump conformers, J. Biol. Chem., 286, 35044, 10.1074/jbc.M111.266759 · DOI · Paper page
  52. Lockamy, 2011, Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure, Biochem. Biophys. Res. Commun., 408, 388, 10.1016/j.bbrc.2011.04.023 · DOI
  53. Chen, 2005, Role of leucine 31 of phospholamban in structural and functional interactions with the Ca2+ pump of cardiac sarcoplasmic reticulum, J. Biol. Chem., 280, 10530, 10.1074/jbc.M414007200 · DOI
  54. Liu, 1998, Guidelines for membrane protein engineering derived from de novo designed model peptides, Biopolymers, 47, 41, 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X · DOI

Cited by

Metadata

Authors
Ceholski, D. K., Trieber, C. A., & Young, H. S.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2012-05
Volume
287
Issue
20
Pages
16521-16529
ISSN
0021-9258
Cited by
63
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.